NASDAQ: SYRASyra Health Corp Stock
$1.07+0.05 (+4.9%)
Updated Apr 26, 2024
SYRA Price
$1.07
Fair Value Price
N/A
Market Cap
$15.05M
52 Week Low
$0.81
52 Week High
$8.37
P/E
-1.78x
P/B
3.75x
P/S
0.9x
PEG
N/A
Dividend Yield
N/A
Revenue
$5.52M
Earnings
-$2.94M
Gross Margin
25.6%
Operating Margin
-52.3%
Profit Margin
-53.3%
Debt to Equity
0.23
Operating Cash Flow
-$3M
Beta
1.26
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
SYRA Overview
Syra Health Corp., a healthcare services company, provides health education, population health management, behavioral and mental health, healthcare workforce, and digital health services in the United States. It offers health education services, including medical communications, patient education, and healthcare training; and population health management services, such as analytics as a service, epidemiology, and health equity analytics solutions. The company also engages in developing Syrenity, an on-demand telehealth platform for mental health services. In addition, the company provides healthcare staffing solutions; and digital health solutions comprising digital transformation, cloud and security, artificial intelligence, patient engagement, and health apps. It serves mental health hospitals and organizations, including government agencies, integrated health networks, managed care entities, and pharmaceutical manufacturers. Syra Health Corp. was incorporated in 2020 and is headquartered in Carmel, Indiana.
Zen Score
–
Industry Average (30)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how SYRA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SYRA is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
SYRA is good value based on its book value relative to its share price (3.75x), compared to the US Medical Care Facilities industry average (4.49x)
P/B vs Industry Valuation
SYRA is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more SYRA due diligence checks available for Premium users.
Be the first to know about important SYRA news, forecast changes, insider trades & much more!
SYRA News
Valuation
SYRA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.78x
Industry
-1.17x
Market
41.14x
SYRA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.75x
Industry
4.49x
SYRA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
SYRA's financial health
Profit margin
Revenue
$1.8M
Net Income
-$995.3k
Profit Margin
-56.4%
SYRA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
SYRA's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$4.9M
Liabilities
$910.1k
Debt to equity
0.23
SYRA's short-term assets ($4.78M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SYRA's short-term assets ($4.78M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SYRA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.8M
Investing
$0.0
Financing
$5.0M
SYRA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
SYRA vs Medical Care Facility Stocks
Syra Health Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.